Amgen Issues Epogen and Procrit Recall - - BioPharm International


Amgen Issues Epogen and Procrit Recall

Today, Amgen issued a voluntary recall of 201 lots of Epogen and 155 lots of Procrit (epoitin alfa) because of concern about very thin glass flakes in the vials. The flakes, or lamellae, result from the interaction of the formulation with the glass vials over the shelf life of the product.

The company has announced that according to evaluations conducted by Amgen and Centocor, the risk to patients who have received product included in the recall is low. To date, there have been no complaints or adverse events reported which can be directly attributed to the presence of glass lamellae.  

Epogen and Procrit are both manufactured by Amgen. Epogen is sold by Amgen in the United States.  Centocor Ortho Biotech Products is the authorized distributor of Procrit in the United States.

Lists of the recalled product lots and expiration are available at at and

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here